目的 分析促紅細(xì)胞生成素聯(lián)合納洛酮治療新生兒缺氧缺血性腦病的效果。方法 選擇2015年1月—2018年1月西電集團(tuán)醫(yī)院收治的110例新生兒缺氧缺血性腦病患者，隨機(jī)分為兩組。對照組采用納洛酮治療，觀察組采用促紅細(xì)胞生成素聯(lián)合納洛酮治療。兩組均治療14 d。比較兩組的癥狀恢復(fù)時(shí)間，血清S100β蛋白和神經(jīng)元特異性烯醇化酶（NSE）水平，并進(jìn)行新生兒神經(jīng)行為（NBNA）測定和隨訪后遺癥發(fā)生情況。結(jié)果 觀察組新生兒缺氧缺血性腦病的有效率（94.54%）明顯高于對照組（76.36%），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組的肌張力恢復(fù)時(shí)間、意識恢復(fù)時(shí)間和原始反射恢復(fù)時(shí)間均明顯短于對照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清NSE和S100β蛋白水平明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組的血清NSE和S100β蛋白水平明顯低于對照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組治療后3、7、14 d的NBNA評分均明顯高于治療前，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組明顯高于對照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組后遺癥發(fā)生率（3.64%）明顯低于對照組（9.09%），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 促紅細(xì)胞生成素聯(lián)合納洛酮可以有效改善新生兒缺氧缺血性腦病的神經(jīng)系統(tǒng)癥狀，降低血清S100β蛋白和NSE水平，減少后遺癥的發(fā)生，提高療效，值得應(yīng)用推廣。

Objective To investigate the efficacy of erythropoietin combined with naloxone in the treatment of neonatal hypoxic ischemic encephalopathy. Methods Selected 110 cases of patients with neonatal hypoxic ischemic encephalopathy who were treated in our hospital from January 2015 to January 2018, divided into two groups randomly. The control group was treated with naloxone, while the observation group was treated with erythropoietin combined with naloxone. Results The effective rate of the observation group was significantly higher than control group (P<0.05); the muscle tension, consciousness and primal reflex recovery time in the observation group were significantly shorter than control group (P<0.05); the serum S100β protein and NSE levels in the observation group were significantly lower than control group (P<0.05). The scores of NBNA at 3, 7 and 14 days after treatment in both groups were significantly higher than those before treatment (P<0.05), especially in the observation group (P<0.05); The incidence of sequela in the observation group was significantly lower than that control group (P<0.05). Conclusion Erythropoietin combined with naloxone can effectively improve the neurological symptoms of neonatal hypoxic-ischemic encephalopathy, reduce the levels of serum S100β protein and NSE, reduce the incidence of sequelae, improve the efficacy.